By Reuters
NYT Business Day
Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. reg...
Published date: November 16, 2019 at 03:46AM
Reuters
New York Times article
No comments:
Post a Comment